by
John R. Fischer, Senior Reporter | May 26, 2020
“I thought that we should really look at this again, now that we’ve got this large database we can work with and try to find out what happened with these patients,” said Berg, who adds that “the important thing about this paper is that these data come from a wide number of facilities across the United States, so it really brings to bear that, yes, this is the appropriate practice and yes, you still need to see these patients in six months.”
A similar study presented at the ARRS 2019 Annual Meeting in Hawaii this month
deemed short-interval follow-up MR as an efficient imaging method for identifying early-stage breast cancer among findings that are deemed probably to be benign. Using it could help to avoid unnecessary biopsies, according to its authors.

Ad Statistics
Times Displayed: 45539
Times Visited: 1299 Ampronix, a Top Master Distributor for Sony Medical, provides Sales, Service & Exchanges for Sony Surgical Displays, Printers, & More. Rely on Us for Expert Support Tailored to Your Needs. Email info@ampronix.com or Call 949-273-8000 for Premier Pricing.
“Many patients and providers question the utility of BI-RADS 3 in MR, particularly as some insurers do not cover the costs of the short interval follow-up MR,” said co-author Christine Edmonds, of the department of radiology at Massachusetts General Hospital in a statement. “This study clarifies that short interval follow-up MR is a valuable method of identifying early-stage breast cancer while avoiding unnecessary biopsies.”
The study by Berg and her colleagues was published in
Radiology.
Back to HCB News